Morgan Stanley Vericel Corp Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Vericel Corp stock. As of the latest transaction made, Morgan Stanley holds 530,136 shares of VCEL stock, worth $27.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

530,136

Previous 504,400 5.1%

Holding current value

$27.6 Million

Previous $21.3 Million 36.6%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$40.05 - $59.11 $1.03 Million - $1.52 Million	25,736 Added 5.1%	530,136 $29.1 Million
Q3 2024 Nov 14, 2024	BUY	$42.25 - $53.56 $2.07 Million - $2.63 Million	49,034 Added 10.77%	504,400 $21.3 Million
Q2 2024 Oct 17, 2024	SELL	$41.71 - $52.9 $120,708 - $153,092	-2,894 Reduced 0.63%	455,366 $20.9 Million
Q2 2024 Aug 14, 2024	SELL	$41.71 - $52.9 $120,708 - $153,092	-2,894 Reduced 0.63%	455,366 $20.9 Million
Q1 2024 Oct 17, 2024	BUY	$32.52 - $52.33 $94,112 - $151,443	2,894 Added 0.64%	458,260 $23.8 Million
Q1 2024 Aug 16, 2024	SELL	$32.52 - $52.33 $27.3 Million - $43.9 Million	-839,586 Reduced 64.69%	458,260 $23.8 Million
Q1 2024 May 15, 2024	SELL	$32.52 - $52.33 $27.3 Million - $43.9 Million	-839,586 Reduced 64.69%	458,260 $23.8 Million
Q4 2023 Aug 16, 2024	BUY	$30.85 - $37.09 $26 Million - $31.2 Million	842,480 Added 185.01%	1,297,846 $46.2 Million
Q4 2023 Feb 13, 2024	SELL	$30.85 - $37.09 $1.81 Million - $2.17 Million	-58,580 Reduced 4.32%	1,297,846 $46.2 Million
Q3 2023 Nov 15, 2023	BUY	$31.69 - $39.25 $21.9 Million - $27.2 Million	692,260 Added 104.23%	1,356,426 $45.5 Million
Q2 2023 Aug 14, 2023	BUY	$29.0 - $38.37 $2.84 Million - $3.76 Million	97,985 Added 17.31%	664,166 $25 Million
Q1 2023 May 15, 2023	SELL	$23.85 - $31.34 $11 Million - $14.4 Million	-460,779 Reduced 44.87%	566,181 $16.6 Million
Q4 2022 Feb 14, 2023	SELL	$17.65 - $27.37 $8.14 Million - $12.6 Million	-461,279 Reduced 30.99%	1,026,960 $27.1 Million
Q3 2022 Nov 14, 2022	SELL	$22.62 - $32.54 $4.19 Million - $6.03 Million	-185,444 Reduced 11.08%	1,488,239 $34.5 Million
Q2 2022 Oct 27, 2022	BUY	$22.88 - $39.45 $23.3 Million - $40.2 Million	1,018,393 Added 155.41%	1,673,683 $42.1 Million
Q2 2022 Aug 15, 2022	BUY	$22.88 - $39.45 $23.3 Million - $40.2 Million	1,018,393 Added 155.41%	1,673,683 $42.1 Million
Q1 2022 Oct 27, 2022	SELL	$31.69 - $43.29 $32.3 Million - $44.1 Million	-1,018,393 Reduced 60.85%	655,290 $25 Million
Q1 2022 May 13, 2022	BUY	$31.69 - $43.29 $11.8 Million - $16.1 Million	371,447 Added 130.86%	655,290 $25 Million
Q4 2021 Feb 14, 2022	SELL	$35.2 - $52.6 $42,028 - $62,804	-1,194 Reduced 0.42%	283,843 $11.2 Million
Q3 2021 Nov 15, 2021	BUY	$46.35 - $59.75 $13.2 Million - $17 Million	285,037 New	285,037 $13.9 Million

Others Institutions Holding VCEL

# of Institutions

291

Shares Held

50.7M

Call Options Held

98.2K

Put Options Held

135K

View Full List

About Vericel Corp

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.45B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

More about VCEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account